Official Guidance on Vaccines with Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not outright ban vaccines but requires caution. The prescribing information states live vaccines are not recommended during treatment due to infection risk from immunosuppression. Inactivated (non-live) vaccines can generally be given, though antibody responses may be reduced.[1]
Live vs. Inactivated Vaccines: Key Differences
- Live vaccines (e.g., MMR, varicella, oral polio, yellow fever): Avoid during Cosentyx use and for 4-6 weeks after stopping, as they replicate and could cause disease in immunocompromised patients.
- Inactivated vaccines (e.g., flu shot, Tdap, pneumococcal, COVID-19, shingles recombinant like Shingrix): Safe to administer; no increased risk beyond standard precautions. Studies show they remain effective, though titers might be lower—booster doses could help.[1][2]
COVID-19 Vaccines Specifically
mRNA COVID-19 vaccines (Pfizer, Moderna) and protein-based ones (Novavax) are inactivated and recommended during Cosentyx. Real-world data from psoriasis patients on biologics, including secukinumab, confirm no excess adverse events post-vaccination. The American Academy of Dermatology endorses them without pausing therapy.[3]
Timing and Practical Advice
- Get non-live vaccines before starting Cosentyx if possible.
- No need to pause Cosentyx for routine inactivated shots—discuss with your doctor for personalized timing, especially around infections.
- Post-vaccination monitoring: Watch for typical side effects; report unusual symptoms promptly.
Potential Risks and Patient Concerns
Cosentyx raises infection risk overall (e.g., upper respiratory), which could amplify post-vaccine reactions, but data shows no causal link to severe vaccine complications. Patients with active infections should delay vaccination. Consult your rheumatologist or dermatologist—guidelines from Novartis and rheumatology societies stress individualized assessment over blanket rules.[1][4]
What Studies Show
Phase III trials and post-marketing data (e.g., SCULPTURE study) report low infection rates with inactivated vaccines. A 2023 review in Rheumatology found secukinumab users had comparable COVID-19 vaccine immunogenicity to healthy controls, with mild side effects in <10%.[2][5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: Rheumatology Oxford Journals - Vaccine Response in IL-17 Inhibitors
[3]: AAD Guidelines on COVID-19 Vaccines for Psoriasis Patients
[4]: ACR Guidelines on Vaccinations in Rheumatic Diseases
[5]: PubMed - Secukinumab and Vaccine Safety Review